Opko Health Inc. (NASDAQ:OPK), biotechnology stocks has appointed Akhtar Ashfaq as the company’s Senior Vice President in charge of Clinical Research and Development at the Renal Division. The appointment takes effect immediately. In this position Dr. Ashfaq will help in the adoption of RAYALDEE®(calcifediol) by medical professionals handling patients with chronic kidney disease at the 3rd or 4th stage. He will also help in steering the development of RAYALDEE and its adoption towards secondary hyperparathyroidism (SHPT) treatment among adults with advanced stage chronic kidney disease and deficiency of vitamin D. Dr. Ashfaq will also help the development and adoption of ALPHAREN® (fermagate) tablets which are used in hyperphosphatemia treatment among adults with advanced stage CKD.
Before his appointment Dr. Ashfaq worked at AstraZeneca as head of the CKD program within Global Medical Affairs. He worked with Amgen as Medical Director and North American Medical Lead for Aranesp and Epogen before joining Astra Zeneca. He brings on board a wide clinical experience spanning 15 years.
While acknowledging the appointment OPKO Health MD, Chairman and Chief Executive Officer Phillip Frost said the company stands to benefit from Dr. Ashfaq adding that he will be pivotal in the development, commercialization and marketing of the company’s new products for CKD patients.
OPKO Health is one of the top biotech stocks and a diversified medical company focused on setting up industry leading positions in a rapidly growing market environment. The company has developed the Bio-Reference Laboratories which is the third largest clinical laboratory focused on genetic testing. It also boosts a strong sales and marketing team comprising of 400 highly qualified people. This group is tasked with the responsibility of driving the company’s growth and leveraging new products. OPKO Health’s pharmaceutical business includes RAYALDEE which has been approved by FDA for 3-4 stage SHPT treatment. OPKO Health has also produced VARUBI™ for treatment of nausea and vomiting caused by chemotherapy. VARUBI™ is awaiting approval by FDA. OPKO Health now joins the list of biotech stocks companies with clinical trials and drugs waiting FDA approval.